Binding of bisphenol A, bisphenol AF, and bisphenol S on the androgen receptor: Coregulator recruitment and stimulation of potential interaction sites

Toxicology in Vitro

Volumn 44, Issue , 2017, Pages 287-302

  Perera, Lalith ^a   Li, Yin ^b   Coons, Laurel A ^b   Houtman, Rene ^c   van Beuningen, Rinie ^c   Goodwin, Bonnie ^d   Auerbach, Scott S ^b   Teng, Christina T ^b  

^a Genome Integrity and Structural Biology Laboratory   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c PamGene International BV   (Netherlands)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Androgen receptor (AR); Binding sites; BPA analogues; Coregulators peptide

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ANDROGEN RECEPTOR; BISPHENOL AF; BISPHENOL S; METRIBOLONE; PEPTIDE DERIVATIVE; PHENOL DERIVATIVE; REGULATOR PROTEIN; UNCLASSIFIED DRUG; 4,4'-HEXAFLUORISOPROPYLIDENE DIPHENOL; AR PROTEIN, HUMAN; BENZHYDRYL DERIVATIVE; BIS(4-HYDROXYPHENYL)SULFONE; ENDOCRINE DISRUPTOR; SULFONE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; RECEPTOR BINDING; SIMULATION; GENETICS; METABOLISM; TUMOR CELL LINE;

BENZHYDRYL COMPOUNDS; BINDING SITES; CELL LINE, TUMOR; ENDOCRINE DISRUPTORS; HUMANS; MOLECULAR DYNAMICS SIMULATION; PHENOLS; RECEPTORS, ANDROGEN; SULFONES;

EID: 85026774804     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2017.07.020     Document Type: Article

References (40)

1. [Anonymous], Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second e.O.R.T.C. workshop, held on 16–17 March, 1979, in The Netherlands cancer institute. Eur. J. Cancer 16 (1980), 1513–1515.
2. Aarts, J.M., Wang, S., Houtman, R., van Beuningen, R.M., Westerink, W.M., Van De Waart, B.J. et al., Robust array-based coregulator binding assay predicting eralpha-agonist potency and generating binding profiles reflecting ligand structure. Chem. Res. Toxicol. 26 (2013), 336–346.
3. Brooke, G.N., Parker, M.G., Bevan, C.L., Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene 27 (2008), 2941–2950.
4. Buchanan, G., Yang, M., Harris, J.M., Nahm, H.S., Han, G., Moore, N. et al., Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 15 (2001), 46–56.
5. Dai, C., Heemers, H., Sharifi, N., Androgen signaling in prostate cancer. Cold Spring Harb. Perspect. Med., 2017, 10.1101/cshperspect.a030452.
6. Estebanez-Perpina, E., Arnold, L.A., Nguyen, P., Rodrigues, E.D., Mar, E., Bateman, R. et al., A surface on the androgen receptor that allosterically regulates coactivator binding. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 16074–16079.
7. Feng, W., Ribeiro, R.C., Wagner, R.L., Nguyen, H., Apriletti, J.W., Fletterick, R.J. et al., Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 280 (1998), 1747–1749.
8. Foulds, C.E., Feng, Q., Ding, C., Bailey, S., Hunsaker, T.L., Malovannaya, A. et al., Proteomic analysis of coregulators bound to eralpha on DNA and nucleosomes reveals coregulator dynamics. Mol. Cell 51 (2013), 185–199.
9. He, B., Wilson, E.M., Electrostatic modulation in steroid receptor recruitment of lxxll and fxxlf motifs. Mol. Cell. Biol. 23 (2003), 2135–2150.
10. Heery, D.M., Kalkhoven, E., Hoare, S., Parker, M.G., A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387 (1997), 733–736.
11. Helsen, C., Claessens, F., Looking at nuclear receptors from a new angle. Mol. Cell. Endocrinol. 382 (2014), 97–106.
12. Hodgson, M.C., Astapova, I., Cheng, S., Lee, L.J., Verhoeven, M.C., Choi, E. et al., The androgen receptor recruits nuclear receptor corepressor (n-cor) in the presence of mifepristone via its n and c termini revealing a novel molecular mechanism for androgen receptor antagonists. J. Biol. Chem. 280 (2005), 6511–6519.
13. Hodgson, M.C., Shen, H.C., Hollenberg, A.N., Balk, S.P., Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor. Mol. Cancer Ther. 7 (2008), 3187–3194.
14. Houtman, R., de Leeuw, R., Rondaij, M., Melchers, D., Verwoerd, D., Ruijtenbeek, R. et al., Serine-305 phosphorylation modulates estrogen receptor alpha binding to a coregulator peptide array, with potential application in predicting responses to tamoxifen. Mol. Cancer Ther. 11 (2012), 805–816.
15. Hu, X., Lazar, M.A., The cornr motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 402 (1999), 93–96.
16. Kazmin, D., Prytkova, T., Cook, C.E., Wolfinger, R., Chu, T.M., Beratan, D. et al., Linking ligand-induced alterations in androgen receptor structure to differential gene expression: a first step in the rational design of selective androgen receptor modulators. Mol. Endocrinol. 20 (2006), 1201–1217.
17. Koppen, A., Houtman, R., Pijnenburg, D., Jeninga, E.H., Ruijtenbeek, R., Kalkhoven, E., Nuclear receptor-coregulator interaction profiling identifies trip3 as a novel peroxisome proliferator-activated receptor gamma cofactor. Mol. Cell. Proteomics 8 (2009), 2212–2226.
18. Kumar, R., McEwan, I.J., Allosteric modulators of steroid hormone receptors: structural dynamics and gene regulation. Endocr. Rev. 33 (2012), 271–299.
19. Luccio-Camelo, D.C., Prins, G.S., Disruption of androgen receptor signaling in males by environmental chemicals. J. Steroid Biochem. Mol. Biol. 127 (2011), 74–82.
20. McEwan, I.J., Intrinsic disorder in the androgen receptor: identification, characterisation and drugability. Mol. BioSyst. 8 (2012), 82–90.
21. McEwan, I.J., Androgen receptor modulators: a marriage of chemistry and biology. Future Med. Chem. 5 (2013), 1109–1120.
22. McKenna, N.J., Lanz, R.B., O'Malley, B.W., Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 20 (1999), 321–344.
23. Millard, C.J., Watson, P.J., Fairall, L., Schwabe, J.W., An evolving understanding of nuclear receptor coregulator proteins. J. Mol. Endocrinol. 51 (2013), T23–36.
24. Munuganti, R.S., Hassona, M.D., Leblanc, E., Frewin, K., Singh, K., Ma, D. et al., Identification of a potent antiandrogen that targets the bf3 site of the androgen receptor and inhibits enzalutamide-resistant prostate cancer. Chem. Biol. 21 (2014), 1476–1485.
25. Nagy, L., Kao, H.Y., Love, J.D., Li, C., Banayo, E., Gooch, J.T. et al., Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13 (1999), 3209–3216.
26. Nishimura, K., Ting, H.J., Harada, Y., Tokizane, T., Nonomura, N., Kang, H.Y. et al., Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Res. 63 (2003), 4888–4894.
27. O'Malley, B.W., McKenna, N.J., Coactivators and corepressors: what's in a name?. Mol. Endocrinol. 22 (2008), 2213–2214.
28. Osguthorpe, D.J., Hagler, A.T., Mechanism of androgen receptor antagonism by bicalutamide in the treatment of prostate cancer. Biochemistry 50 (2011), 4105–4113.
29. Rehan, M., Ahmad, E., Sheikh, I.A., Abuzenadah, A.M., Damanhouri, G.A., Bajouh, O.S., AlBasri, S.F., Assiri, M.M., Beg, M.A., Androgen and progresterone receptors are targets for bisphenol A (BPA), 4-methyl-2,4-bis-CP-Hydroxyphenyl)Pent-1-Ene-A potent metabolite of BPA and 4-Tert-Octylphenol: a computational insight. PLoS One, 10, 2015, e0138438.
30. Rochester, J.R., Bisphenol a and human health: a review of the literature. Reprod. Toxicol. 42 (2013), 132–155.
31. Rochester, J.R., Bolden, A.L., Bisphenol s and f: a systematic review and comparison of the hormonal activity of bisphenol a substitutes. Environ. Health Perspect. 123 (2015), 643–650.
32. Safe, S., Environmental estrogens: roles in male reproductive tract problems and in breast cancer. Rev. Environ. Health 17 (2002), 253–262.
33. Shi, X.B., Ma, A.H., Xia, L., Kung, H.J., de Vere White, R.W., Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 62 (2002), 1496–1502.
34. Sidorkiwicz, I., Zareba, K., Wolczynski, S., Czemiecki, J., Endocrine-disrupting chemicals-Mechanisms of action on male reproductive system. Toxicol. Ind. Health, 2017 (p748233717695160).
35. Tan, M.H., Li, J., Xu, H.E., Melcher, K., Yong, E.L., Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharmacol. Sin. 36 (2015), 3–23.
36. Teng, C., Goodwin, B., Shockley, K., Xia, M., Huang, R., Norris, J. et al., Bisphenol a affects androgen receptor function via multiple mechanisms. Chem. Biol. Interact. 203 (2013), 556–564.
37. van de Wijngaart, D.J., Dubbink, H.J., van Royen, M.E., Trapman, J., Jenster, G., Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol. Cell. Endocrinol. 352 (2012), 57–69.
38. Wang, S., Houtman, R., Melchers, D., Aarts, J., Peijnenburg, A., van Beuningen, R. et al., A 155-plex high-throughput in vitro coregulator binding assay for (anti-)estrogenicity testing evaluated with 23 reference compounds. ALTEX 30 (2013), 145–157.
39. Wetherill, Y.B., Petre, C.E., Monk, K.R., Puga, A., Knudsen, K.E., The xenoestrogen bisphenol a induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol. Cancer Ther. 1 (2002), 515–524.
40. Xu, X., Yang, W., Wang, X., Li, Y., Wang, Y., Ai, C., Dynamic communication between androgen and coactivator: mutually induced conformational perturbations in androgen receptor ligand-binding domain. Proteins 79 (2011), 1154–1171.